Literature DB >> 21245937

Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.

Jian Zhang1, Sudha Sud, Kosuke Mizutani, Margaret R Gyetko, Kenneth J Pienta.   

Abstract

Macrophages within the tumor microenvironment promote angiogenesis, extracellular matrix breakdown, and tumor cell migration, invasion, and metastasis. Activation of the urokinase plasminogen activator (uPA) and its receptor (uPAR) axis promotes prostate cancer tumorigenicity, invasion, metastasis, and survival within the tumor microenvironment. The link between macrophage infiltration and the uPA/uPAR axis in prostate cancer development has not been established, although it has been reported that uPA plays a critical role inmonocyte and macrophage chemotaxis. In this study, murine prostate cancer RM-1 cells were subcutaneously inoculated into wild-type (WT), uPA(-/-), and uPAR(-/-) mice. Tumor volume was significantly diminished in both uPA(-/-) and uPAR(-/-) mice compared with WT controls. Greater inhibition of tumor volume was also observed in uPA(-/-) mice compared with uPAR(-/-) mice, suggesting the important contribution of stromal-derived uPA to sustain the tumor growth. Immunohistochemical staining revealed that tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly lower proliferative indices, higher apoptotic indices, and less neovascularity compared with the tumors in WT mice. Tumors in uPA(-/-) and uPAR(-/-) mice displayed significantly less macrophage infiltration as demonstrated by F4/80 staining and MAC3(+) cell numbers by flow cytometry compared with the tumors from WT mice. These findings suggest that the uPA/uPAR axis acts in both autocrine and paracrine manners in the tumor microenvironment, and activation of uPA/uPAR axis is essential for macrophage infiltration into prostate tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245937      PMCID: PMC3022425          DOI: 10.1593/neo.10728

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  37 in total

1.  Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.

Authors:  L S Gutierrez; A Schulman; T Brito-Robinson; F Noria; V A Ploplis; F J Castellino
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

Review 2.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

3.  Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.

Authors:  Bilal Bin Hafeez; Vaqar Mustafa Adhami; Mohammad Asim; Imtiaz A Siddiqui; Kumar M Bhat; Weixiong Zhong; Mohammad Saleem; Maria Din; Vijayasaradhi Setaluri; Hasan Mukhtar
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 4.  Urokinase plasminogen activator system as a potential target for cancer therapy.

Authors:  Ahmed H Mekkawy; David L Morris; Mohammad H Pourgholami
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

5.  Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation.

Authors:  Yi Lu; Daibang Nie; William T Witt; Qiuyan Chen; Miaoda Shen; Haiyang Xie; Liangxue Lai; Yifan Dai; Jian Zhang
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

6.  Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways.

Authors:  Zhiwei Wang; Yiwei Li; Sanjeev Banerjee; Dejuan Kong; Aamir Ahmad; Veronique Nogueira; Nissim Hay; Fazlul H Sarkar
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

7.  Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration.

Authors:  Scott C Bryer; Giamila Fantuzzi; Nico Van Rooijen; Timothy J Koh
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

Review 8.  Targeting uPA/uPAR in prostate cancer.

Authors:  Y Li; P J Cozzi
Journal:  Cancer Treat Rev       Date:  2007-07-19       Impact factor: 12.111

9.  A novel model of bone-metastatic prostate cancer in immunocompetent mice.

Authors:  Carl A Power; Hnin Pwint; Jeffrey Chan; Jae Cho; Yan Yu; William Walsh; Pamela J Russell
Journal:  Prostate       Date:  2009-11-01       Impact factor: 4.104

Review 10.  Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.

Authors:  G Solinas; G Germano; A Mantovani; P Allavena
Journal:  J Leukoc Biol       Date:  2009-09-09       Impact factor: 4.962

View more
  28 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.

Authors:  Gabriele Eden; Marco Archinti; Ralitsa Arnaudova; Giuseppina Andreotti; Andrea Motta; Federico Furlan; Valentina Citro; Maria Vittoria Cubellis; Bernard Degryse
Journal:  Cell Mol Life Sci       Date:  2017-11-28       Impact factor: 9.261

3.  Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.

Authors:  Kasper Almholt; Ole Didrik Lærum; Boye Schnack Nielsen; Ida Katrine Lund; Leif Røge Lund; John Rømer; Annika Jögi
Journal:  Clin Exp Metastasis       Date:  2015-06-04       Impact factor: 5.150

4.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

5.  Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.

Authors:  Isis C Sroka; Cynthia P Sandoval; Harsharon Chopra; Jaime M C Gard; Sangita C Pawar; Anne E Cress
Journal:  Mol Cancer Res       Date:  2011-08-08       Impact factor: 5.852

6.  Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs).

Authors:  Antonio Sica; Chiara Porta; Sara Morlacchi; Stefania Banfi; Laura Strauss; Monica Rimoldi; Maria Grazia Totaro; Elena Riboldi
Journal:  Cancer Microenviron       Date:  2011-09-24

7.  GM-CSF and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.

Authors:  Roselind S Lam; Neil M O'Brien-Simpson; John A Hamilton; Jason C Lenzo; James A Holden; Gail C Brammar; Rebecca K Orth; Yan Tan; Katrina A Walsh; Andrew J Fleetwood; Eric C Reynolds
Journal:  Immunol Cell Biol       Date:  2015-03-10       Impact factor: 5.126

8.  Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasis of human prostate cancer PC-3M-luciferase cells in an orthotopic xenograft mouse model.

Authors:  Bilal Bin Hafeez; Weixiong Zhong; Joseph W Fischer; Ala Mustafa; Xudong Shi; Louise Meske; Hao Hong; Weibo Cai; Thomas Havighurst; Kyungmann Kim; Ajit K Verma
Journal:  Mol Oncol       Date:  2012-12-14       Impact factor: 6.603

9.  Spontaneous metastasis in congenic mice with transgenic breast cancer is unaffected by plasminogen gene ablation.

Authors:  Kasper Almholt; Anna Juncker-Jensen; Ole Didrik Lærum; Morten Johnsen; John Rømer; Leif Røge Lund
Journal:  Clin Exp Metastasis       Date:  2012-09-21       Impact factor: 5.150

Review 10.  VEGF-initiated angiogenesis and the uPA/uPAR system.

Authors:  Johannes M Breuss; Pavel Uhrin
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.